学会速報レポート

Gastrointestinal Cancers Symposium 2020(ASCO-GI 2020)

海外学会で発表されたホットでタイムリーな演題を専門医が厳選。レポートとコメントを掲載します。

ASCO-GI 2020

2020年1月23日~25日にサンフランシスコで開催の消化器癌シンポジウム2020 より注目演題のレポートを掲載します。

【レポート演題リスト(予定)】 ※諸事情により変更する場合がございます。ご了承ください。

ASCO-GI 2020 FLASH REPORT - Abstract 476 - 肝胆膵癌 Oral

Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
First Author: Peter R. Galle, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 5 - 大腸癌 Oral

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.
First Author: Yoshiaki Nakamura

ASCO-GI 2020 FLASH REPORT - Abstract 281 - 食道癌 Oral

A randomized controlled phase III multicenter study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer: ARTDECO study.
First Author: Maarten C.C.M. Hulshof, MD PhD

ASCO-GI 2020 FLASH REPORT - Abstract 100 - 大腸癌 Poster

VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.
First Author: Takeshi Kato, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 478 - 肝胆膵癌 Oral

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
First Author: Thomas Yau

ASCO-GI 2020 FLASH REPORT - Abstract 7 - 大腸癌 Oral

A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS).
First Author: Yukihide Kanemitsu, MD

ASCO-GI 2020 FLASH REPORT - Abstract 374 - 胃癌 Poster

An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706).
First Author: Akihito Kawazoe

ASCO-GI 2020 FLASH REPORT - Abstract 383 - 胃癌 Poster

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.
First Author: Li-Tzong Chen, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 178 - 大腸癌 Poster

Plasma VEGF-D and PlGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.
First Author: Hiroya Taniguchi, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 278 - 胃癌 Oral Coming Soon

Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).
First Author: Markus H. Moehler, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 638 - 肝胆膵癌 Oral Coming Soon

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma.
First Author: Margaret A. Tempero, MD, FASCO

ASCO-GI 2020 FLASH REPORT - Abstract 1 - 大腸癌 Oral Coming Soon

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
First Author: Aurelien Marabelle, MD, PhD

ASCO-GI 2020 FLASH REPORT - Abstract 133 - 大腸癌 Oral Coming Soon

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Eyal Meiri, MD